Related Experiment Video
Updated: Jun 26, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Molecular Tumor Board-Directed Treatment for Patients with Advanced-Stage Solid Tumors: A Case-Control Real-World
Ben Ponvilawan1, Dhruv Bansal2, Karnav Modi3
1Department of Medicine, Feinberg School of Medicine, Northwestern University, 676 North St. Clair St, Suite 2330, Chicago, IL 60611, USA.
Current Oncology (Toronto, Ont.)
|June 25, 2026
Summary
Molecular tumor boards (MTBs) improve cancer patient survival. Treatments recommended by MTBs significantly increased overall survival, progression-free survival, and time on treatment in advanced cancer patients.
Area of Science:
- Oncology
- Genomics
- Cancer Treatment
Background:
- Interpreting comprehensive genomic testing for cancer treatment is complex.
- Molecular tumor boards (MTBs) facilitate collaborative frameworks for integrating genomic data into patient care plans.
Purpose of the Study:
- To evaluate the impact of molecular tumor board (MTB) recommendations on patient outcomes.
- To assess the feasibility and effectiveness of MTBs in a community cancer center setting.
Main Methods:
- Retrospective observational study of 238 advanced-stage cancer patients (September 2017 - January 2023).
- Patients were grouped based on receiving MTB-recommended treatment versus not.
- Survival outcomes (overall survival, progression-free survival, time on treatment) analyzed using Kaplan-Meier and Cox proportional hazards models.
Main Results:
- 58% of patients received at least one MTB-recommended treatment.
- Patients on MTB-recommended treatment showed significantly increased median overall survival (18.5 vs. 9.1 months), progression-free survival (9.7 vs. 4.3 months), and time on treatment (4.3 vs. 2.8 months).
- Hazard ratios indicated improved survival outcomes with MTB-guided treatment (OS HR 0.64, PFS HR 0.64, ToT HR 0.58).
Conclusions:
- Molecular tumor boards are feasible in community cancer centers.
- MTB recommendations significantly improve survival outcomes for advanced cancer patients.
- MTBs enhance the integration of genomic data into clinical decision-making for improved cancer care.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...